Larimar Therapeutics (LRMR) EBIAT (2016 - 2020)
Historic EBIAT for Larimar Therapeutics (LRMR) over the last 7 years, with Q1 2020 value amounting to -$3.6 million.
- Larimar Therapeutics' EBIAT rose 7255.95% to -$3.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.9 million, marking a year-over-year increase of 3867.13%. This contributed to the annual value of -$45.4 million for FY2019, which is 2601.03% up from last year.
- Per Larimar Therapeutics' latest filing, its EBIAT stood at -$3.6 million for Q1 2020, which was up 7255.95% from -$7.3 million recorded in Q4 2019.
- In the past 5 years, Larimar Therapeutics' EBIAT ranged from a high of -$3.6 million in Q1 2020 and a low of -$17.7 million during Q1 2016
- Over the past 5 years, Larimar Therapeutics' median EBIAT value was -$13.1 million (recorded in 2019), while the average stood at -$13.0 million.
- As far as peak fluctuations go, Larimar Therapeutics' EBIAT crashed by 3165.08% in 2016, and later surged by 7255.95% in 2020.
- Over the past 5 years, Larimar Therapeutics' EBIAT (Quarter) stood at -$10.4 million in 2016, then decreased by 25.35% to -$13.1 million in 2017, then decreased by 11.35% to -$14.6 million in 2018, then skyrocketed by 50.23% to -$7.3 million in 2019, then skyrocketed by 50.38% to -$3.6 million in 2020.
- Its last three reported values are -$3.6 million in Q1 2020, -$7.3 million for Q4 2019, and -$12.9 million during Q3 2019.